ALKERMES, INC. for ALKERMES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - use of FDA approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - use of FDA approved medicines in criminal justice settings
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Health Issues HCR
Discuss need for educational resources and the use of Vivitrol for public health
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Medicare/Medicaid MMM
Maintain the program's six protected classes with respect to depression and schizophrenia
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Pharmacy PHA
DEA regulatory transparency in controlled substances scheduling person DEA regulatory transparency in issuing research licenses and quotas
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.